Can you provide the average price target for ABBVIE INC stock?
39 analysts have analysed ABBV and the average price target is 256.12 USD. This implies a price increase of 28.89% is expected in the next year compared to the current price of 198.71.
NYSE:ABBV • US00287Y1091
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABBVIE INC (ABBV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-04-21 | Canaccord Genuity | Initiate | Buy |
| 2026-04-10 | Guggenheim | Maintains | Buy -> Buy |
| 2026-04-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-02-25 | RBC Capital | Initiate | Outperform |
| 2026-02-20 | Barclays | Initiate | Overweight |
| 2026-02-18 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-05 | UBS | Maintains | Neutral -> Neutral |
| 2026-02-05 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-27 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-08 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-12-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-10 | HSBC | Upgrade | Hold -> Buy |
| 2025-11-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-11-05 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-11-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-03 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-20 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-17 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-10-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-03 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-10-01 | HSBC | Downgrade | Buy -> Hold |
| 2025-09-22 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-17 | Berenberg | Upgrade | Hold -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 54.318B -6.44% | 56.334B 3.71% | 61.16B 8.57% | 68.42B 11.87% | 73.977B 8.12% | 79.312B 7.21% | 83.389B 5.14% | 84.924B 1.84% | 86.73B 2.13% | 88.059B 1.53% | 88.73B 0.76% | |
| EBITDA YoY % growth | 25.251B -11.68% | 24.883B -1.46% | 29.077B 16.85% | 34.36B 18.17% | 37.952B 10.45% | 41.077B 8.23% | 40.135B -2.29% | 39.315B -2.04% | 38.815B -1.27% | 39.343B 1.36% | N/A | |
| EBIT YoY % growth | 16.553B -17.74% | 16.497B -0.34% | 20.938B 26.92% | 32.948B 57.36% | 36.62B 11.14% | 39.37B 7.51% | 43.079B 9.42% | 44.038B 2.23% | 45.267B 2.79% | 46.821B 3.43% | 47.339B 1.11% | |
| Operating Margin | 30.47% | 29.28% | 34.23% | 48.16% | 49.50% | 49.64% | 51.66% | 51.86% | 52.19% | 53.17% | 53.35% | |
| EPS YoY % growth | 11.11 -19.90% | 10.12 -8.91% | 10.00 -1.19% | 14.83 48.29% | 16.41 10.66% | 18.16 10.68% | 19.64 8.13% | 20.18 2.76% | 20.68 2.45% | 21.19 2.48% | 20.87 -1.52% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.80 13.66% | 3.86 29.91% | 3.93 111.04% | 4.02 48.46% | 3.32 18.67% | 4.21 9.03% | 4.26 8.54% | 4.40 9.35% |
| Revenue Q2Q % growth | 15.012B 12.51% | 17.146B 11.17% | 17.741B 12.46% | 18.509B 11.38% | 16.148B 7.57% | 18.194B 6.11% | 18.909B 6.58% | 19.443B 5.05% |
| EBITDA Q2Q % growth | 6.397B 6.26% | 8.897B -9.27% | 9.031B -22.03% | 8.926B -36.01% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 6.415B 61.14% | 8.556B 49.66% | 8.711B 60.39% | 8.692B 49.63% | 7.571B 18.02% | 8.798B 2.83% | 9.322B 7.01% | 9.599B 10.43% |
All data in USD
39 analysts have analysed ABBV and the average price target is 256.12 USD. This implies a price increase of 28.89% is expected in the next year compared to the current price of 198.71.
ABBVIE INC (ABBV) will report earnings on 2026-04-29, before the market open.
The consensus EPS estimate for the next earnings of ABBVIE INC (ABBV) is 2.8 USD and the consensus revenue estimate is 15.01B USD.
The number of analysts covering ABBVIE INC (ABBV) is 39.